# Voyant System

## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTELLIGENT ENERGY SYSTEM</td>
<td>4</td>
</tr>
<tr>
<td>VOYANT MARYLAND FUSION DEVICE</td>
<td>5</td>
</tr>
<tr>
<td>VOYANT 5mm FUSION DEVICE</td>
<td>6</td>
</tr>
<tr>
<td>VOYANT FINE FUSION DEVICE</td>
<td>7</td>
</tr>
<tr>
<td>VOYANT OPEN FUSION DEVICE</td>
<td>8</td>
</tr>
<tr>
<td>VOYANT ELECTROSURGICAL GENERATOR AND ACCESSORIES</td>
<td>9</td>
</tr>
<tr>
<td>FDA 510(K) CLEARANCE – VOYANT ELECTROSURGICAL GENERATOR</td>
<td>10</td>
</tr>
<tr>
<td>FDA 510(K) CLEARANCE – VOYANT MARYLAND FUSION DEVICE</td>
<td>12</td>
</tr>
<tr>
<td>FDA 510(K) CLEARANCE – VOYANT 5mm FUSION DEVICE, 37cm and 44cm</td>
<td>16</td>
</tr>
<tr>
<td>FDA 510(K) CLEARANCE – VOYANT FINE FUSION DEVICE</td>
<td>14</td>
</tr>
<tr>
<td>FDA 510(K) CLEARANCE – VOYANT OPEN FUSION DEVICE</td>
<td>16</td>
</tr>
<tr>
<td>VOYANT EVALUATION AGREEMENT</td>
<td>18</td>
</tr>
<tr>
<td>APPLIED MEDICAL BUSINESS MODEL</td>
<td>19</td>
</tr>
</tbody>
</table>
Voyant
Intelligent Energy System

The Voyant advanced bipolar system collects information about the nature of the tissue within its jaws, rapidly and constantly measures tissue as the energy is applied, and adjusts to provide the optimal amount of energy throughout the seal cycle to create a permanent, fused seal.

Voyant System’s Intelligence

Intelligence is defined as the ability to learn. The Voyant Intelligent Energy system is the only advanced energy solution with the ability to learn from live human tissue. Through gaining an understanding of product use, Applied Medical continues to advance the Voyant technology to better meet specific clinical needs.

Intelligence Gathering

The Voyant device key connected to each handpiece stores activation data from each vessel or tissue bundle sealed throughout the procedure. By collecting device keys, Applied Medical engineers are able to analyze the data to further optimize energy delivery.

Benefits of Voyant Intelligence

The Voyant system’s continual energy optimization means Applied Medical can make each activation more efficient with the potential to speed up seal time, decrease lateral thermal spread and reduce smoke plume. It means the technology has the potential to address energy delivery for even the most challenging tissue types.
**Voyant Maryland Fusion Device**

**Single-Handed 360° Shaft Rotation**
Facilitates easy and accurate jaw placement.

**Single-Action, Curved Jaw with Dissecting Tip**
Allows for optimal control during dissection, greater visualization of the jaws and tracking of the curvature of anatomical structures. Provides enhanced tissue dissection.

**Spring-Loaded Latching Handle**
May result in less hand fatigue when activating and fewer inadvertent activations.

**Handle Lever Insert**
Accommodates various hand sizes.

---

**Voyant Maryland Fusion Device**

<table>
<thead>
<tr>
<th>Model</th>
<th>Modality</th>
<th>Maximum Vessel Size</th>
<th>Shaft Length</th>
<th>Jaw Style</th>
<th>Trocar Compatibility</th>
<th>Seal Length</th>
<th>Cut Length</th>
<th>Jaw Shape</th>
<th>Shaft Rotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>EB215</td>
<td>Advanced bipolar</td>
<td>7mm</td>
<td>37cm</td>
<td>Single action</td>
<td>5mm or larger</td>
<td>20mm</td>
<td>18mm</td>
<td>Curved with dissecting tip</td>
<td>360°</td>
</tr>
<tr>
<td>EB216</td>
<td>Advanced bipolar</td>
<td>7mm</td>
<td>44cm</td>
<td>Single action</td>
<td>5mm or larger</td>
<td>20mm</td>
<td>18mm</td>
<td>Curved with dissecting tip</td>
<td>360°</td>
</tr>
<tr>
<td>EB217</td>
<td>Advanced bipolar</td>
<td>7mm</td>
<td>23cm</td>
<td>Single action</td>
<td>5mm or larger</td>
<td>20mm</td>
<td>18mm</td>
<td>Curved with dissecting tip</td>
<td>360°</td>
</tr>
</tbody>
</table>
Voyant
5mm Fusion Device

Single-Handed 360° Shaft Rotation
Facilitates easy and accurate jaw placement.

Blade Lever

Single-Action, Straight Jaw with Blunt Tip
Allows for optimal control during dissection.

Spring-Loaded Latching Handle
May result in less hand fatigue when activating the fuse button and opening the handle.

Handle Lever Insert
Accommodates various hand sizes.

Voyant 5mm Fusion Device

<table>
<thead>
<tr>
<th>Model</th>
<th>Modality</th>
<th>Maximum Vessel Size</th>
<th>Shaft Length</th>
<th>Jaw Style</th>
<th>Trocar Compatibility</th>
<th>Seal Length</th>
<th>Cut Length</th>
<th>Jaw Shape</th>
<th>Shaft Rotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>EB210</td>
<td>Advanced bipolar 7mm 37cm Single action 5mm or larger 20mm 18mm Straight with blunt tip 360°</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EB211</td>
<td>Advanced bipolar 7mm 44cm Single action 5mm or larger 20mm 18mm Straight with blunt tip 360°</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Voyant Fine Fusion Device

Dual-Action, Curved Jaw with Dissecting Tip
Allows for optimal control during dissection, greater visualization of the jaws and tracking of the curvature of anatomical structures. Provides enhanced fine tissue dissection.

Ring Handle Insert
Accommodates various hand sizes.

Voyant Fine Fusion Device

<table>
<thead>
<tr>
<th>Model</th>
<th>Modality</th>
<th>Maximum Vessel Size</th>
<th>Working Length</th>
<th>Jaw Style</th>
<th>Seal Length</th>
<th>Cut Length</th>
<th>Jaw Shape</th>
</tr>
</thead>
<tbody>
<tr>
<td>EB230</td>
<td>Advanced bipolar</td>
<td>7mm, including head and neck</td>
<td>13.5cm</td>
<td>Dual action</td>
<td>17mm</td>
<td>15mm</td>
<td>Curved with dissecting tip</td>
</tr>
</tbody>
</table>
Voyant
Open Fusion Device

180° Shaft Rotation
Facilitates easy and accurate jaw placement.

Fuse Activation Button

Blade Lever

Dual-Action, Curved Jaw with Blunt Tip
Assists with visualization of the distal end of the jaws.

Spring-Loaded Latching Handle
Facilitates opening of the handle and jaws, minimizing the potential for hand fatigue.

Handle Lever Insert
Accommodates various hand sizes.

Voyant Open Fusion Device

<table>
<thead>
<tr>
<th>Model</th>
<th>Modality</th>
<th>Maximum Vessel Size</th>
<th>Shaft Length</th>
<th>Jaw Style</th>
<th>Seal Length</th>
<th>Cut Length</th>
<th>Jaw Shape</th>
<th>Shaft Rotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>EB240</td>
<td>Advanced bipolar</td>
<td>7mm</td>
<td>20cm</td>
<td>Dual action</td>
<td>40mm</td>
<td>38mm</td>
<td>Curved with blunt tip</td>
<td>180°</td>
</tr>
</tbody>
</table>
Voyant Electrosurgical Generator and Accessories

Advanced Energy
The EA020 Voyant generator is an advanced bipolar electrosurgical generator compatible with second-generation Voyant devices.

Seamless Software Updates
The Voyant Intelligent Energy system delivers the latest technology embedded in each device key.

Easy Preventive Maintenance
Output verification testing can be run at the touch of a button with the results displayed on-screen.

Sleek and Simple Design
The Voyant generator boasts a small profile and an easy-to-use user interface.

Plug and Play System
Simply turn on the generator and connect a Voyant device. The system is ready to use!

Voyant Electrosurgical Generator and Accessories

<table>
<thead>
<tr>
<th>Model</th>
<th>Description</th>
<th>Modality</th>
<th>Product Size/Weight</th>
<th>Ports</th>
</tr>
</thead>
<tbody>
<tr>
<td>EA020</td>
<td>Voyant electrosurgical generator</td>
<td>Advanced bipolar</td>
<td>35.1cm x 30.5cm x 11.3cm (6.6kg)</td>
<td>1</td>
</tr>
<tr>
<td>EX150</td>
<td>Voyant cart</td>
<td>N/A</td>
<td>66cm x 51cm x 106cm (60kg)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
October 11, 2018
Applied Medical Resources Corp.
Mr. Andrew Nguyen
Regulatory Affairs Specialist I
22872 Avenida Empresa
Rancho Santa Margarita, California 92688

Re: K182244
  Trade/Device Name: Voyant Electrosurgical Generator
  Regulation Number: 21 CFR 878.4400
  Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories
  Regulatory Class: Class II
  Product Code: GEI
  Dated: September 24, 2018
  Received: September 25, 2018

Dear Mr. Nguyen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmncfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part...
medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/Reportaproblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Long H. Chen -S
2018.10.11 15:42:40
-04'00'

Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
April 8, 2020

Applied Medical Resources Corp.
Blake Stacy
Regulatory Affairs Analyst
22872 Avenida Empresa
Rancho Santa Margarita, California 92688

Re: K200598
Trade/Device Name: Voyant Maryland Fusion Device
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories
Regulatory Class: Class II
Product Code: GEI
Dated: March 9, 2020
Received: March 9, 2020

Dear Blake Stacy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products), good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Long H. Chen -S
Digitally signed by Long H. Chen
Date: 2020.04.08 09:46:19 -04'00'

Long Chen, Ph.D.
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
July 6, 2016

Applied Medical Resources
Ms. Jessica Cho
Manager, Regulatory Affairs
22872 Avenida Empresa
Rancho Santa Margarita, CA 92688

Re: K153017
Trade/Device Name: Voyant Fine Fusion
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: Class II
Product Code: GEI
Dated: May 31, 2016
Received: June 1, 2016

Dear Ms. Cho:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Jennifer R. Stevenson -A

For Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
June 5, 2020

Applied Medical Resources Corp.
Sherif Nakhla
Regulatory Affairs Specialist
22872 Avenida Empresa
Rancho Santa Margarita, California 92688

Re: K201212
Trade/Device Name: Voyant Open Fusion Device
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting And Coagulation Device And Accessories
Regulatory Class: Class II
Product Code: GEI
Dated: May 5, 2020
Received: May 5, 2020

Dear Sherif Nakhla:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be classification products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
statutes and regulations administered by other Federal agencies. You must comply with all the Act’s
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-
combination-products); good manufacturing practice requirements as set forth in the quality systems (QS)
regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for
combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-
542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part
803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-
mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including
information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See
the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE
by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Long H. Chen, Ph.D.
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
VOYANT EVALUATION AGREEMENT

PREVIEW EVALUATION PERIOD

<table>
<thead>
<tr>
<th>Start Date</th>
<th>Scheduled Start Date</th>
<th>Scheduled End Date</th>
</tr>
</thead>
</table>

We have reviewed and understand the clinical evaluation process. The goal of this evaluation is to collect objective clinical feedback about the functionality and acceptability of the Applied Medical products and thereby provide the basis for support to contract the Applied Medical product.

Product shall be purchased for the agreed-upon length of the evaluation period at the established price of $_____ per handpiece.

Returns associated with this evaluation will not incur a restocking fee and must be received by Applied Medical 10 business days after the agreed-upon end date of each individual facility’s evaluation period. Applied Medical reserves the right, at the end of the evaluation, to limit or decline these special terms for returns, exchanges or credits.

Any capital equipment provided by Applied Medical for use during the evaluation process remains the property of Applied Medical. This signed document acknowledges that __________(quantity) EA020, Voyant electrosurgical generator(s) will be provided for use during the evaluation process. Such equipment shall be returned upon Applied Medical’s request. Per existing regulatory guidance, the time period for any evaluation of capital equipment shall not exceed the amount of time reasonably necessary to allow for an adequate evaluation, given the circumstances of the Customer, and in no event shall it be longer than 90 days.

ACCOUNT OR HEALTH SYSTEM

ACCOUNT NUMBER(S) (LIST ALL THAT APPLY)

CUSTOMER

Signature

Printed Name

Title

Email Address

Date

APPLIED MEDICAL

Signature

Printed Name

Title

Date
ABOUT APPLIED MEDICAL

Founded in 1987 and headquartered in Southern California, Applied Medical is a rapidly growing, global organization.

As a new generation medical device company, we are equally committed to improving both the affordability and the accessibility of high-quality healthcare. We are proud to have a significant and sustainable impact on healthcare by delivering technologies that enhance clinical care and satisfy the pressing economic needs of our customers.

Our dedicated Field Implementation team works with hospital administration teams, operating suite management and additional team members to plan a professionally implemented surgical device conversion and ensure a seamless transition to Applied Medical products. Applied Medical representatives are available on an ongoing basis for training and support of the hospital staff.

BUSINESS MODEL

Applied Medical is guided by the belief that we are responsible for satisfying the three fundamental healthcare needs – cost containment, enhanced clinical outcomes and unrestricted choice. In light of this belief, we invest heavily in team members, R&D and advanced manufacturing technologies in order to develop the products and processes that allow us to satisfy our customers’ needs.

One of the main facets of our business model is vertical integration. Instead of outsourcing our operations, we continuously focus on expanding our areas of expertise and manufacturing capabilities. As a vertically integrated organization, we manufacture our products in-house at our facilities in Southern California and Amersfoort, Netherlands, and provide exceptional customer service, support and education.

Our high level of vertical integration allows us to quickly and efficiently make product enhancements and develop new technologies, reducing the amount of time required for innovative ideas to positively impact patient care. Vertical integration also allows us to control costs, closely manage supply lines, and ensure the highest product quality, availability and compliance.

Visit www.appliedmedical.com/voyant for more information.

Devices listed may not be approved in all markets. Please contact your Field Implementation team member for more information on availability.